Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Market Spotlight: Uterine Cancer

$1,318.00

This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
February 1, 2022
Find out more
U.S. Markets for Biologic and Tissue Engineered Devices – Cardiovascular and Neurological Products

$3,750.00

U.S. Markets for Biologic and Tissue Engineered Devices – Cardiovascular and Neurological Products, March 2015
September 22, 2016
Find out more
Knee Replacement Implants Market

$4,750.00

This medical market and technology report provides a comprehensive discussion of the global market for knee replacement implants. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets, which includes all other countries.
November 18, 2020
Find out more
Abraxane
Read More
Abraxane (nab-paclitaxel; Bristol-Myers Squibb) is a novel albumin-bound formulation of paclitaxel. Paclitaxel is an insoluble taxane classified as an anti-microtubule agent; it stops the growth of tumors by inhibiting mitosis during metaphase.
February 26, 2020
Find out more
Market Spotlight: Overactive Bladder

$1,318.00

This Market Spotlight report covers the Overactive Bladder market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 25, 2022
Find out more
U.S. Markets for Sports Medicine Products

$4,750.00

This dynamic new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. sports medicine devices market.
September 22, 2016
Find out more
Market Spotlight: Hodgkin’s Lymphoma

$1,318.00

This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
May 23, 2022
Find out more
Market Spotlight: Primary Sclerosing Cholangitis (PSC)

$1,318.00

This Market Spotlight report covers the Primary Sclerosing Cholangitis (PSC) market, comprising key pipeline drugs, recent events and analyst opinion, upcoming events, clinical trials, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast.
May 25, 2022
Find out more
Opioids and Chronic Neuropathic Pain Management KOL Interview

$599.00

Biomedtracker interviewed a neurologist based in the United States who currently treats over 1000 patients with chronic neuropathic pain per year to determine his current treatment practices for indications including fibromyalgia and views on the use of opioids and abuse-deterrent opioids.
March 9, 2017
Find out more
Idalopirdine
Read More
Idalopirdine (Lundbeck/Otsuka) is an active, potent, and selective oral 5-hydroxytryptamine-6 receptor antagonist.
September 2, 2016
Find out more
Big Pharma Diversification Strategies

$2,995.00

Pressures ranging from continually declining revenues as a result of generics and impending biosimilars launches, to slow R&D productivity and market access restrictions could cause the Big Pharma peer set to evaluate business opportunities beyond pharmaceuticals.
March 4, 2018
Find out more
Xalkori
Read More
Xalkori (crizotinib; Pfizer/Merck KGaA) is a selective, adenosine triphosphate-competitive small molecule multi-kinase inhibitor of mesenchymal epithelial transition growth factor
August 30, 2018
Find out more
NASH KOL Insight Interview #1

$599.00

The prevalence data would suggest that in the US population about 30% of our population has fatty liver or NAFLD and of those 25% may have NASH and of those patients with NASH 25% percent may have fibrosis and progress to cirrhosis. It’s almost a pyramid effect, there may be 80 million Americans walking around with NAFLD, but to climb up to the top of the pyramid and develop cirrhosis would be about 5% of that total population, but that’s still significant because that would mean that the prevalence of cirrhosis [due to NASH] will exceed that of hepatitis C-related cirrhosis ten-fold
February 20, 2014
Find out more
Tyvaso for Pulmonary Arterial Hypertension

$89.00

The literature search was undertaken via multiple search engines and strategies with review of cited and associated articles to provide a comprehensive discussion on the topic. Expert opinion: While safe and well tolerated, inhaled treprostinil sodium should be limited, based on available data, to use as add-on therapy for patients with Group I pulmonary hypertension not effectively controlled on oral therapy.
November 29, 2016
Find out more
Harvoni
Read More
Harvoni is a fixed-dose combination of Gilead’s nucleotide NS5B inhibitor sofosbuvir and the company’s NS5A inhibitor ledipasvir. Within the US, Harvoni is currently approved for the treatment of genotype 1/4/5/6 (GT-1/4/5/6) hepatitis C virus patients, while in the EU the combination is approved for the treatment of GT-1/3/4/5/6 patients.
November 6, 2017
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *